



**FOR IMMEDIATE RELEASE**

## **SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation**

### ***Abraxis Bioscience LLC. dismissed complaint against SPARC***

**MUMBAI – December 09, 2019**, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that Abraxis Bioscience LLC. has dismissed the patent infringement complaint filed against SPARC regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension).

"We are very pleased that Abraxis Bioscience LLC. has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals," said Anil Raghavan, CEO of SPARC.

SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.

#### **About PICS (Paclitaxel Injection Concentrate for Suspension):**

PICS (Paclitaxel Injection Concentrate for Suspension) is a Cremophor® and Albumin-free formulation of Paclitaxel. PICS seeks the same indications as Abraxane®. Since it is Cremophor®-free, it can be diluted in either a PVC or non-PVC sterile infusion bag with an appropriate volume of 5% w/v Dextrose injection. Premedication to prevent hypersensitivity is generally not needed prior to administration of PICS. A New Drug Application for PICS is currently under review by the USFDA.

#### **About SPARC (CIN: L73100GJ2006PLC047837):**

Sun Pharma Advanced Research Company Ltd. ('SPARC') is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at [www.sparc.life](http://www.sparc.life).

#### **Disclaimer:**

Statements in this document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

#### **Media Contacts:**

Jaydeep Issrani  
Tel +91 22 66455645, Extn: 5787  
Tel Direct +91 22 6645 5787  
Mobile +91-9820216916  
E mail [jaydeep.issrani@sparcmail.com](mailto:jaydeep.issrani@sparcmail.com)

*®, TM - All brand names and trademarks are the property of respective owners.*

**Sun Pharma Advanced Research Company Ltd.**

17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.  
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: [www.sparc.life](http://www.sparc.life)

Registered Office : SPARC, Akota Road, Akota, Vadodara - 390 020, Gujarat, India.